In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats

British Journal of Cancer

Volumn 79, Issue 3-4, 1999, Pages 433-439

  Van Der Veen, A H ^a   Seynhaeve, A L B ^a   Breurs, J ^a   Nooijen, P T G A ^b   Marquet, Rl ^a   Eggermont, Amm ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Isolated kidney perfusion; Rats; Tumour necrosis factor

Indexed keywords

MELPHALAN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; ISOLATED KIDNEY; KIDNEY FAILURE; KIDNEY PERFUSION; MALE; MAXIMUM PERMISSIBLE DOSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; RAT; REGIONAL PERFUSION; RESPIRATORY FAILURE; SEPTIC SHOCK; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY; KIDNEY FAILURE; MALE; MELPHALAN; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; OSTEOSARCOMA; RATS; SHOCK, SEPTIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032957355     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690067     Document Type: Article

References (42)

1. Affres H, Perez J, Hagege J, Fouqueray B, Kornprobst M, Ardaillou R and Baud L (1991) Desferrioxamine regulates tumor necrosis factor release in mesangial cells. Kidney Int 39: 822-830
2. Asbach HW and Bersch W (1980) The effect of in situ isolated perfusion of experimental renal tumors with cytotoxic agents in high concentration. Urol Int 35: 112-124
3. Asher A, Mule JJ, Reichert CM, Shiloni E and Rosenherg SA (1987) Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138: 963-974
4. Baud L and Ardaillou R (1995) Tumor necrosis factor in renal injury. Miner Electrolyte Metab 21: 336-341
5. Borel Rinkes IHM, de Vries MR, Jonker AM, Swaak TJG, Hack CE, Nooijen PTGA, Wiggers T and Eggermont AMM (1997) Isolated hepatic perfusion in the pig with TNF-α with and without melphalan. Br J Cancer 75: 1447-1453
6. Brouckaert PGG, Leroux-Rouls GG, Guisez Y, Tavernier J and Fiers W (1986) In vivo anti tumor activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma on a syngeneic murine melanoma. Int J Cancer 38: 763-769
7. Dealtry GB, Naylor MS, Fiers W and Balkwill FR (1987) The effect of recombinant human tumor necrosis factor on growth and macromolecular synthesis of human epithelial cells. Exp Cell Res 170: 428-438
8. Eggermont AMM, Liénard D, Schrafford Koops H, Rosenkaimer F and Lejeune FJ (1993) Treatment of irresectable soft tissue sarcomas of the limbs by isolation perfusion with high dose TNFα in combination with interferon-gamma and melphalan. In Tumour Necrosis Factor: Molecular and Cellular Biology and Clinical Relevance. Fiers W and Buurman WA (eds.). pp. 239-243. Karger: Basle
9. Eggermont AMM, Schraffordt Koops H, Liénard D, Kroon BRR, van Geel AN, Hoekstra HJ and Lejeune FJ (1996a) Isolated limb perfusion with high dose tumor necrosis factor-α in combination with Interferon-γ and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol 14: 2653-2665
10. Eggermont AMM, Schraffordt Koops H, Klausner J, Kroon BBR, Schlag PM, Liénard D, Van Geel AN, Hoekstra HJ, Meller I, Nieweg OE, Kettelhack C, Ben-Ari G, Pector JC and Lejeune FJ (1996b) Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced extremity sarcomas. The cumulative multicenter European experience. Ann Surg 224: 756-765
11. Fajardo LF, Kwan HH, Kowalski J, Prionas SD and Allison AC (1992) Dual role of tumor necrosis factor-α in angiogenesis. Am J Pathol 140: 539-544
12. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S and Gutterman JU (1988) A phase 1 trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 6: 1328-1334
13. Fine LG (1986) The biology of renal hypertrophy. Kidney Int 29: 619-634
14. Fraker DL, Alexander HR and Thom AK (1994) Use of tumor necrosis factor in isolated hepatic perfusion. Circulatory Shock 44: 45-50
15. Gaskill HV (1988) Continuous infusion of tumor necrosis factor: mechanisms of toxicity in the rat. J Surg Res 44: 664-671
16. Hieber U and Heim ME (1994) Tumor necrosis factor for the treatment of malignancies. Oncology 51: 142-153
17. Kahky MP, Daniel CO, Cruz AB and Gaskill HV (1990) Portal infusion of tumor necrosis factor increases mortality in rats. J Surg Res 49: 138-145
18. Kallinowski F, Schaeffer C, Tyler G and Vaupel P (1989) In vivo targets of recombinant human tumor necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted art tumors. Br J Cancer 60: 555-560
19. Kramer SM and Carver ME (1986) Serum-free in vivo bioassay for the detection of tumor necrosis factor. J Immunol Methods 93: 201-206
20. Lejeune FJ, Liénard D, Leyvraz S and Mirimanoff RO (1993) Regional therapy of melanoma. Eur J Cancer 29A: 606-612
21. Liénard D. Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60
22. Liénard D, Eggermont AMM, Schraffordt Koops H, Kroon BB, Rosenkaimer F, Autier P and Lejeune FJ (1994) Isolated perfusion of the limb with high-dose tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. Melanoma Res 4: 21-26
23. Maessen JG, Greve JWM and Buurman WA (1991) Increased sensitivity to endotoxemia by tissue necrosis. Surgery 109: 154-159
24. Manusama ER, Marquet RL, Durante NMC and Eggermont AMM (1994) Ischemia promotes the antitumour effect of tumor necrosis factor-α (TNFα) in isolated limb perfusion in the rat. Reg Cancer Treat 7: 155-159
25. Manusama ER, Nooijen PTGA, Stavast J, Durante NMC, Marquet RL and Eggermont AMM (1996a) Synergistic antitumor effect of recombinant human tumor necrosis factor α with melphalan in isolated limb perfusion in the rat. Br J Surg 83: 551-555
26. Manusama ER, Stavast J, Durante NMC, Marquet RL and Eggermont AMM (1996b) Isolated limb perfusion with TNFα and melphalan in a rat osteosarcoma model: a new anti-tumor approach. Eur J Surg Oncol 22: 152-157
27. Marquet RL, Westbroek DL and Jeekel J (1984) Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 33: 689-692
28. Nooijen PTGA, Manusama ER, Schalkwijk L, de Waal RMW, Eggermont AMM and Ruiter DJ (1996) Histopathologic analysis of the synergistic antitumor effects of TNFα and melphalan in an isolated limb perfusion model of rat sarcoma. Br J Cancer 74: 1908-1915
29. Pass HI, Mew DJY, Kranda KC, Temeck BK, Donington JS and Rosenberg SA (1996) Isolated lung perfusion with tumor necrosis factor for pulmonary metastases. Ann Thorac Surg 61: 1609-1617
30. Pogrebniak HW, Witt CJ, Terrill R, Kranda K, Travis WD, Rosenberg SA and Pass HI (1994) Isolated lung perfusion with tumor necrosis factor: a swine model in preparation of human trials. Ann Thorac Surg 57: 1477-1483
31. Prehn RT and Main JW (1957) Immunity to methylcholantrene-induced sarcomas. J Natl Cancer Inst 18: 769-778
32. Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K and Mori J (1988) Recombinant human tumor necrosis factor-α: thrombus formation is a cause of anti-tumour activity. Int J Cancer 41: 243-247
33. Sidhu RS and Bollon AP (1993) Tumor necrosis factor activities and cancer therapy - a perspective. Pharm Ther 57: 79-128
34. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112
35. Spriggs DR and Yates SW (1992) Cancer chemotherapy. Experience with TNF administration in humans. In Tumor Necrosis Factors: The Molecules and their Emerging Role in Medicine. Beutler B (ed.), pp. 383-106. Raven Press: New York
36. Spriggs DR, Sherman ML, Michie H, Arthur KA, Imamura K, Willmore D, Frei 3rd F and Kufe DW (1988) Rccombinant human tumor necrosis factor administered as a 24 h intravenous infusion. A phase I and pharmacologic study. J Natl Cancer Inst 80: 1039-1044
37. Tipping PG, Leong TW and Holdsworth SR (1991) Tumor necrosis factor production by glomerular macrophages in anti-glomerular basement membrane glomerulonephritis in rabbits. Lab Invest 65: 272-279
38. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD, Shires GT and Cerami A (1986) Shock and tissue injury induced by recombinant human cachectin. Science 234: 470-474
39. Walther MM, Jennings SB, Choyke PL, Andrich M, Hurley K, Marston Linehan W, Rosenberg SA and Alexander RB (1996) Isolated perfusion of the kidney with tumor necrosis factor for localized renal-cell carcinoma. World J Urol 14: S2-S7
40. Watanabe N, Niitsu Y, Umeno H, Sone H, Neda H, Yamauchi N, Maeda M and Urushizaki I (1988) Toxic effect of TNF on tumor vasculature in mice. Cancer Res 49: 2179-2183
41. Weksler B, Schneider A, Ng B and Burt ME (1993) Isolated single lung perfusion in the rat: an experimental model. J Appl Physiol 74: 2736-2739
42. Weksler B, Blumberg D, Lenert JT, Ng B, Fong Y and Burt ME (1994) Isolated single-lung perfusion with TNF-α in a rat sarcoma lung metastasis model. Ann Thorac Surg 58: 328-332